Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpRegen subretinal cell therapy for dry age-related macular degeneration with geographic atrophy
MOH_2017-04-05_000294Phase 2Recruiting
- Sponsor
- CellCure Neurosciences Ltd.
- Start
- Feb 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of OpRegen in age-related macular degeneration (AMD) and geographic atrophy (GA) (2 arms), sponsored by CellCure Neurosciences Ltd. Started Feb 2015; status: recruiting.
02
Drugs
OpRegen
03
Conditions
age-related macular degeneration (AMD)geographic atrophy (GA)
Beyond the preview
Go deeper on MOH_2017-04-05_000294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-05_000294.